Clinical trials: CVD - Cardiovascular Disease
Multiple Myeloma
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients
BKT-140 drug substance is a highly selective chemokine receptor (CXCR4) antagonist, which is developed by Biokine as a novel therapy for Multiple Myeloma (MM, a type of blood cancer).
- Trial name
- NCT01010880
- Testing
- BKT140
- Where
- 2 sites in Israel
- Volunteers
- 16 people
- Sponsor
- Biokine Therapeutics Ltd
Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation
A Study Assessing Arrhythmia Mapping With a Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter
The purpose of this study is to assess the performance and safety for the use of the investigational catheter for intracardiac mapping in the atria and ventricles.
- Conditions
- Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Ventricular Tachycardia
- Trial name
- COSMOS (NCT05373862)
- Testing
- Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter
- Where
- 4 sites in Belgium, Croatia and 1 more
- Volunteers
- 40 people
- Sponsor
- Biosense Webster, Inc.
Chronic Kidney Disease, Type 2 Diabetes Mellitus
A Study Using Surveys to Learn More About Treatment With Steroidal Mineralocorticoid Receptor Antagonists, How They Are Used, What Side Effects They Have, and How Satisfied People Who Receive Them Are in the US
This is an observational study in which patients with chronic kidney diseases (CKD), type 2 diabetes (T2D) or heart failure (HF) who are current or past users of sMRA therapies are studied.
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus, Heart Failure
- Trial name
- NCT05407662
- Testing
- sMRA therapies
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Bayer
Heart Failure, Congestive, Ventricular Fibrillation
Safety and Effectiveness of Cardiac Resynchronization Therapy With Defibrillation
The purpose of this study was to determine if cardiac resynchronization therapy when combined with defibrillation is safe and effective in the treatment of symptomatic heart failure.
- Conditions
- Heart Failure, Congestive, Ventricular Fibrillation, Tachycardia, Ventricular
- Trial name
- NCT00387803
- Testing
- Cardiac Resynchronization Therapy with Defibrillation
- Where
- United States
- Volunteers
- 581 people
- Sponsor
- Boston Scientific Corporation
Diabetic Foot
The Pharmacokinetic Study of WH-1 Ointment in Subjects With Chronic Diabetic Foot Ulcers
The objective of this study is to evaluate the systemic exposures of WH-1 ointment which includes Salvigenin and Asiaticoside A in subjects with chronic diabetic foot ulcers following topical application of WH-1.
- Trial name
- NCT02353273
- Testing
- WH-1 ointment
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- Oneness Biotech Co., Ltd.
Atherosclerosis
Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)
This will be an exploratory, open-label, single sequence, two part study (Part A and an optional Part B). The aim of this study will be to assess whether systemic inhibition of Lipoprotein associated phospholipase A2 (Lp-PLA2) in…
- Trial name
- NCT02058641
- Testing
- Darapladib
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- GlaxoSmithKline
Thrombosis
Vitamin K2 Intervention in Patients With Vitamin K Antagonists
The objective of the SAFE K study is to demonstrate that in patients treated with the antagonists of vitamin K (VKA), a daily intake of vitamin K2 (75 micrograms/day) as naturally produced by the ferments used in fermented dairy…
- Trial name
- SAFEK (NCT01533441)
- Testing
- Vitamin K2
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Danisco
Hypertension,Essential, Systolic Hypertension
Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study
This washout protocol is structured as a sub-study for patients willing to participate after finishing the double blind randomised phase of the clinical trial, NCT02837445. Devices will be turned off for a week approximately.
- Trial name
- NCT05086523
- Testing
- Programmable Hypertension Control (BackBeat Moderato), Pacing (BackBeat Moderato)
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 28 people
- Sponsor
- BackBeat Medical Inc
Acute Myocardial Infarction, Acute Myocardial Ischemia
Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction
- Conditions
- Acute Myocardial Infarction, Acute Myocardial Ischemia, STEMI - ST Elevation Myocardial Infarction
- Trial name
- NCT03486080
- Testing
- Dutogliptin Tartrate, Filgrastim Injectable Product
- Where
- 12 sites in Austria, Belgium and 3 more
- Volunteers
- 49 people
- Sponsor
- Recardio, Inc.
Fabry Disease
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
An open-label study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of migalastat treatment in pediatric subjects 2 to < 12 years of age with Fabry disease and with amenable GLA variants.
- Trial name
- NCT06904261
- Testing
- Migalastat HCl 20 mg
- Where
- 12 sites in United States, Belgium and 4 more
- Volunteers
- 8 people
- Sponsor
- Amicus Therapeutics
Atrial Fibrillation (AF), Stroke
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
- Trial name
- AZALEA-TIMI 71 (NCT04755283)
- Testing
- Abelacimab, Rivaroxaban
- Where
- 92 sites in United States, Canada and 5 more
- Volunteers
- 1,287 people
- Sponsor
- Anthos Therapeutics, Inc.
Aortic Stenosis
PRospective Observation of Aortic reGuRgitation aftEr TAVI and progreSS Over Time: PROGRESS PVL Registry
The purpose of this post-market registry is to collect and monitor ongoing safety and performance clinical data of the ACURATE neo™ Aortic Bioprosthesis, and the ACURATE TF™ Transferral Delivery System, when used as per IFU.
- Trial name
- PROGRESS (NCT02987894)
- Testing
- ACURATE neo™ Aortic Bioprosthesis
- Where
- 23 sites in Canada, Germany and 2 more
- Volunteers
- 500 people
- Sponsor
- Symetis SA
Aortic Arch Aneurysm
The NEXUS™ Compassionate Use Data Collection Study
A Multicenter, observational Data Collection Study to Evaluate the Safety and Performance of the Nexus™ Aortic Arch Stent Graft System in patients that were implanted with the device as part of Compassionate Use Procedures.
- Trial name
- NCT03420066
- Testing
- Retrospective data collection
- Where
- 4 sites in Italy, New Zealand and 1 more
- Volunteers
- 7 people
- Sponsor
- Endospan Ltd.
Hypertension
A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
This is an open label, long term extension to Study AMB115811. All subjects may remain in the extension study for a minimum of 18 months.
- Trial name
- AMBER II (NCT01894022)
- Testing
- Ambrisentan 5 mg
- Where
- 50 sites in United States, Argentina and 14 more
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Primary Erythromelalgia, Inherited Erythromelalgia
Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)
The purpose of this study is to determine whether XPF-001 is safe and effective in the treatment of pain caused by Inherited Erythromelalgia (IEM).
- Trial name
- NCT01090622
- Testing
- XPF-001
- Where
- Netherlands
- Volunteers
- 4 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Coronary Artery Disease
DynamX Sirolimus Study Sirolimus Eluting Coronary Bioadaptor System
To confirm the safety and performance of the DynamX Sirolimus-eluting Coronary Bioadaptor System (SECBS) in de novo native coronary artery lesions using clinical and imaging endpoints.
- Trial name
- NCT03634020
- Testing
- DynamX Sirolimus-eluting Coronary Bioadaptor System
- Where
- 7 sites in New Zealand
- Volunteers
- 44 people
- Sponsor
- Elixir Medical Corporation
Hypertension
A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy
Phase 4 clinical trial to Evaluate the blood pressure lowering effect of a Candesartan/Hydrochlorothiazide(Candemore Plus Tab) versus Candesartan/Amlodipine(Cantabell Tab) in Hypertensive Patients
- Trial name
- NCT04521023
- Testing
- Cantabell Tab, Candemore Plus Tab
- Where
- 14 sites in South Korea
- Volunteers
- 132 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Atrial Fibrillation
Retrospective Registry Providing Baseline Data on the Outcome of Left Atrial (LA) or LA Appendage (LAA) Thrombus in Patients With Nonvalvular Atrial Fibrillation (AF) or Atrial Flutter After Standard of Care (SoC) Anticoagulant Therapy
Thrombus outcome data will be collected retrospectively during 2011-2012 as a historical baseline of SoC with oral VKA (Vitamin K Antagonist(s) for the treatment of patients with nonvalvular AF or atrial flutter documented with…
- Trial name
- CLOT-AF (NCT01928979)
- Testing
- no drug
- Where
- 7 sites in Bulgaria, France and 5 more
- Volunteers
- 160 people
- Sponsor
- Bayer
Osteoarthritis With Controlled Hypertension
Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension
This randomized study will compare the effect of lumiracoxib, ibuprofen and placebo on 24-hour blood pressure profile and on urinary excretions of eicosanoids in controlled hypertensive patients who have osteoarthritis.
- Trial name
- NCT00419796
- Testing
- Lumiracoxib
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Novartis
Subdural Hematoma, Subdural Hematoma, Chronic
Study On Histoacryl Used For Embolization Of Middle Meningeal Artery (MMA) In Chronic Subdural Hematoma (CSDH)
The aim of the study is to proof the effectiveness of Histoacryl® on preventing recurrence or progression of subdural hematoma after embolization of the middle meningeal artery.
- Trial name
- HARMONY (NCT07258069)
- Testing
- Histoacryl®
- Where
- 6 sites in Japan
- Volunteers
- 178 people
- Sponsor
- Aesculap AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.